Acute myeloid leukemia in elderly adults

✍ Scribed by J. Tucker; A. E. Thomas; W. M. Gregory; T. S. Ganesan; S. T. A. Malik; J. A. L. Amess; J. Lim; L. Willis; A. Z. S. Rohatiner; T. A. Lister

• Publisher: John Wiley and Sons
• Year: 1990
• Tongue: English
• Weight: 487 KB
• Volume: 8
• Category: Article
• ISSN: 0278-0232
• DOI: 10.1002/hon.2900080103

✦ Synopsis

One hundred and fifteen previously untreated adults aged over 60 years were referred to St Bartholomew's Hospital between 1978 and 1986 for management of acute myeloid leukemia (AML). Twenty-seven patients received symptomatic or palliative treatment only because combination chemotherapy was considered inappropriate.

Eighty-eight patients received intensive chemotherapy with curative intent. There was a 48 per cent 'early death' rate and a 24 per cent incidence of resistant disease; complete remission (CR) was achieved in 25/88 patients (28 per cent). By multivariate analysis, a blast count < 50 x lo9/] at presentation was the only factor predictive for achievement of CR whilst the latter and a presentation blast count < 50 x 109/1 predicted for superior survival.

Treatment was often curtailed on account of unacceptable toxicity; only 2/88 patients received the planned six cycles of treatment. Two patients died in CR. Four patients are alive in first CR at 3-9 years from treatment; one is alive in second CR following meningeal relapse. Overall survival was significantly worse than that of a contemporaneous group of adults aged 15-59 years treated at this hospital, but duration of CR was comparable.

There are great difficulties involved in the intensive treatment of AML in elderly adults, but the major survival benefit gained by achieving CR should stimulate the search for better tolerated but still curative regimens.